Patricia Cogram obtained her BSc in Genetics from University College London (UCL) and completed a PhD in Neurodevelopment at UCL. She undertook postdoctoral training at the Laboratory for Molecular Cell Biology (LMCB), Medical Research Council (MRC), London. In 2008, she joined the faculty at UCL and established her independent research program at the Institute of Child Health, focusing on molecular mechanisms underlying neurodevelopment and disease.

In 2013, she relocated to Chile to join the Fraunhofer-Gesellschaft Chile Research Center for Systems Biotechnology (CSB), where she served as Director of the Biomedicine Division for five years. Following the closure of Fraunhofer Chile, she continued her research as an associate investigator at the Institute of Ecology and Biodiversity (IEB), where part of her laboratory remains based.

In 2025, she joined Fundación Ciencia & Vida. Her laboratory integrates basic and translational research, with a focus on Fragile X syndrome through the FRAXA–Drug Validation Initiative (FRAXA-DVI). In parallel, her group develops AI-driven strategies to identify and validate pharmacological targets for rare forms of autism, Alzheimer’s disease, obsessive–compulsive disorder, Kabuki syndrome, and related conditions.

Her work bridges evolutionary biology, neuroscience, and translational medicine, combining in vivo models, cellular systems, and computational approaches to understand disease mechanisms and accelerate therapeutic development in collaboration with academic and industry partners. She leads multidisciplinary teams and international collaborative research programs.